logo
CAPITOL ROUNDUP: Sen. Yaw measure to establish Independent Energy Office approved by Senate

CAPITOL ROUNDUP: Sen. Yaw measure to establish Independent Energy Office approved by Senate

Yahoo09-02-2025

Feb. 9—WILKES-BARRE — Legislation establishing an Independent Energy Office (IEO) in Pennsylvania was approved this week by the state Senate, according to Sen. Gene Yaw, R-Williamsport, sponsor of the measure.
"Pennsylvania has one of the most diverse energy portfolios in the United States," Yaw said. "I believe an Independent Energy Office can streamline our approach to responsible energy policy and ensure a more cohesive strategy for managing our vast natural resources."
Senate Bill 187, Yaw said, would model the IEO after Pennsylvania's Independent Fiscal Office (IFO), which was created by Act 120 of 2010 and Act 100 of 2016. Yaw said the IFO does not support or oppose any policy it analyzes and discloses the methodologies, data sources and assumptions used in published reports and estimates.
Numerous industry representatives expressed support for the bill, including the Pennsylvania Chamber of Business and Industry.
"Sen. Yaw's leadership on this legislation is a win for Pennsylvania's economy and our energy future," said Amy Brinton, the Chamber's director of government affairs. "Establishing an Independent Energy Office will help us collect and analyze the data and insights needed to make smart energy decisions, strengthen grid reliability and keep Pennsylvania competitive. Energy drives our economy, and this bill helps secure our position as a global energy leader."
The bill now moves to the House of Representatives for consideration.
Rep. Meuser votes to permanently schedule fentanyl analogues
U.S. Rep. Dan Meuser, R-Dallas, this week supported H.R. 27 — the HALT Fentanyl Act — bipartisan legislation that would permanently classify fentanyl-related substances as Schedule I under the Controlled Substances Act (CSA).
Without congressional action, the current temporary scheduling expires on March 31, 2025.
Fentanyl overdoses continue to devastate communities nationwide, including those in Pennsylvania. In 2023, fentanyl was linked to 76% of Pennsylvania's 4,721 overdose deaths.
Rep. Meuser said keeping these lethal substances under Schedule I gives law enforcement the tools to go after traffickers while allowing researchers to understand fentanyl analogs better.
In 2018, Meuser said the DEA, under President Trump, issued an emergency order placing all fentanyl-related substances under strict federal control. Congress has since extended this order multiple times, but the HALT Fentanyl Act would make it permanent, reinforcing efforts to combat the growing opioid crisis.
In 2024, Rep. Meuser said U.S. Customs and Border Protection seized more than 21,000 pounds of fentanyl at U.S. borders — enough to kill more than 4 billion people. This lethal drug is 50 times stronger than heroin and 100 times more potent than morphine, fueling a skyrocketing rise in overdoses across the country.
"In 2023, a Pennsylvanian lost their life to a drug overdose every two hours," said Rep. Meuser. "The HALT Fentanyl Act is a commonsense, bipartisan measure that gives law enforcement the authority to target traffickers, while allowing researchers to study these dangerous substances contributing to the opioid crisis."
Rep. Meuser said the HALT Fentanyl Act passed the House with overwhelming bipartisan support, 312 — 108, and now awaits Senate consideration.
Sen. Fetterman advocates reform in mental health support for servicemembers
U.S. Sen. John Fetterman, D-Braddock, this week sent a letter to Lieutenant General Telita Crosland, Director of the Defense Health Agency, urging the Department of Defense (DoD) to consider allocating funds for new mental health care application programming and reform existing efforts.
In the letter, Sen. Fetterman writes:
"As DoD considers how to spend its greater than $60 billion annual budget for military health care funding in Fiscal Year 2026, I urge the Department to consider allocating funds for new mental health care application programming. We know this funding will pay for itself long term — the estimated return on investment is about $4 for every $1 spent. Prioritizing creative, preventative care measures like mobile applications will equip our service members with the tools and resources they need to navigate personal adversity and avoid mental health emergencies."
In his letter, Sen. Fetterman highlighted how mental health mobile applications have proven to be effective in managing depression and reducing related symptoms among users. These types of apps are typically free or low-cost to users, discreet for use at a moment's notice, and can be used without cellular service or WiFi, which is crucial if a service member is deployed.
However, despite their potential, Sen. Fetterman said DoD's existing apps are underutilized — of the mobile apps currently available to service members, only two were used by more than 1,500 individuals over a three-month period studied by DoD.
Sen. McCormick announces commissions to identify U.S. Marshal, U.S. Attorney candidates
U.S. Sen. Dave McCormick, R-Pittsburgh, this week announced that his office will establish independent commissions to identify U.S. Attorney and U.S. Marshal candidates to fill vacancies in the Eastern, Middle, and Western Districts of Pennsylvania.
The three commissions — one in each of the three districts — will be comprised of 8 to 10 members led by a chair and will be tasked with vetting candidates and making recommendations.
"I want to ensure that the people of Pennsylvania have strong U.S. Attorneys and U.S. Marshals working for them to prosecute criminals and keep our communities safe," Sen. McCormick said. "I'm establishing these commissions to ensure that the process for filling these vacancies is rigorous, fair, and produces exceptional candidates who are prepared to serve and protect all Pennsylvanians."
Sen. McCormick's office will soon name the members and chairs of each commission. His office will also provide information for how to apply to be considered for the U.S. Attorney and U.S. Marshal positions.
For questions, contact pacommission@mccormick.senate.gov.
Reach Bill O'Boyle at 570-991-6118 or on Twitter @TLBillOBoyle.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities
Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities

Yahoo

time6 days ago

  • Yahoo

Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities

Press Release Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company's Executive Committee. This appointment is part of EUROAPI's ongoing FOCUS-27 transformation plan and reinforces its position as a European leader in the API and CDMO sectors. In his new role, Frédéric Robert will be responsible for creating commercial and organizational synergies between the API Solutions and CDMO operations, delivering our FOCUS-27 sales plan and redefining a global sales strategy for the company. He will also be responsible for expanding the group's presence in its strategic markets and with its strategic clients, and optimizing its customer approach with integrated, high-value-added solutions. 'We are delighted to welcome Frédéric Robert to our team,' said David Seignolle, EUROAPI Chief Executive Officer. 'His extensive expertise in the pharmaceutical industry and CDMO space and his strategic vision for international markets will be invaluable assets to accelerate our growth. This appointment reflects our commitment to enhancing the convergence between our API and CDMO activities to deliver even more integrated and effective solutions for our clients.' Frédéric Robert brings a wealth of experience in the pharmaceutical industry, having held senior leadership roles at NAOS Bioderma, Fareva, and more recently at Aptar, where he served as Vice President of EMEA Sales & Customs Development. He has led several operations across Europe and North America, giving him a comprehensive understanding of the entire value chain, from API production to CDMO and CMO services. Frédéric Robert, Chief Commercial OfficerFrédéric Robert, a French national, joins EUROAPI after more than 25 years of experience in the development and commercialization of pharmaceutical products within international organizations. He previously held the position of Vice President of Sales & Customs Development EMEA at Aptar, overseeing nine commercial regions. Prior to this, Frédéric spent over a decade at Fareva as Senior Vice President of Global Sales & Marketing, where he led global commercial operations and served on the group's Executive Committee. Frédéric has also held several senior roles at Institut Esthederm and NAOS Bioderma, overseeing various subsidiaries across Central Europe and North America. There, he was responsible for business development, subsidiary management, and international expansion. He holds a Master's degree in International Marketing from the Dublin City University and a Master's degree in Business Administration (AES) from the University Jean Moulin Lyon 3. About EUROAPIEUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers' and patients' needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities. Taking action for health by enabling access to essential therapies inspires our 3,430 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at and follow us on LinkedIn. Media Relations contact:Laurence BollackTel.: +33 (0)6 81 86 80 19mr@ Investor Relations contact:Sophie Palliez-CapianTel.: +33 (0)6 87 89 33 Certain information contained in this press release is forward looking and not historical data. These forward-looking statements are based on opinions, projections and current assumptions including, but not limited to, assumptions concerning the Group's current and future strategy, financial and non-financial future results and the environment in which the Group operates, as well as events, operations, future services or product development and potential. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Forward looking statements and information do not constitute guarantees of future performances, and are subject to known or unknown risks, uncertainties and other factors, a large number of which are difficult to predict and generally outside the control of the Group, which could cause actual results, performances or achievements, or the results of the sector or other events, to differ materially from those described or suggested by these forward-looking statements. These risks and uncertainties include those that are indicated and detailed in Chapter 3 'Risk factors' of the Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers, AMF) on April 1, 2025. These forward-looking statements are given only as of the date of this press release and the Group expressly declines any obligation or commitment to publish updates or corrections of the forward-looking statements included in this press release in order to reflect any change affecting the forecasts or events, conditions or circumstances on which these forward-looking statements are based. Attachment EUROAPI - Press release - June 4, 2025Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities
Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities

Yahoo

time6 days ago

  • Yahoo

Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities

Press Release Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company's Executive Committee. This appointment is part of EUROAPI's ongoing FOCUS-27 transformation plan and reinforces its position as a European leader in the API and CDMO sectors. In his new role, Frédéric Robert will be responsible for creating commercial and organizational synergies between the API Solutions and CDMO operations, delivering our FOCUS-27 sales plan and redefining a global sales strategy for the company. He will also be responsible for expanding the group's presence in its strategic markets and with its strategic clients, and optimizing its customer approach with integrated, high-value-added solutions. 'We are delighted to welcome Frédéric Robert to our team,' said David Seignolle, EUROAPI Chief Executive Officer. 'His extensive expertise in the pharmaceutical industry and CDMO space and his strategic vision for international markets will be invaluable assets to accelerate our growth. This appointment reflects our commitment to enhancing the convergence between our API and CDMO activities to deliver even more integrated and effective solutions for our clients.' Frédéric Robert brings a wealth of experience in the pharmaceutical industry, having held senior leadership roles at NAOS Bioderma, Fareva, and more recently at Aptar, where he served as Vice President of EMEA Sales & Customs Development. He has led several operations across Europe and North America, giving him a comprehensive understanding of the entire value chain, from API production to CDMO and CMO services. Frédéric Robert, Chief Commercial OfficerFrédéric Robert, a French national, joins EUROAPI after more than 25 years of experience in the development and commercialization of pharmaceutical products within international organizations. He previously held the position of Vice President of Sales & Customs Development EMEA at Aptar, overseeing nine commercial regions. Prior to this, Frédéric spent over a decade at Fareva as Senior Vice President of Global Sales & Marketing, where he led global commercial operations and served on the group's Executive Committee. Frédéric has also held several senior roles at Institut Esthederm and NAOS Bioderma, overseeing various subsidiaries across Central Europe and North America. There, he was responsible for business development, subsidiary management, and international expansion. He holds a Master's degree in International Marketing from the Dublin City University and a Master's degree in Business Administration (AES) from the University Jean Moulin Lyon 3. About EUROAPIEUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers' and patients' needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities. Taking action for health by enabling access to essential therapies inspires our 3,430 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at and follow us on LinkedIn. Media Relations contact:Laurence BollackTel.: +33 (0)6 81 86 80 19mr@ Investor Relations contact:Sophie Palliez-CapianTel.: +33 (0)6 87 89 33 Certain information contained in this press release is forward looking and not historical data. These forward-looking statements are based on opinions, projections and current assumptions including, but not limited to, assumptions concerning the Group's current and future strategy, financial and non-financial future results and the environment in which the Group operates, as well as events, operations, future services or product development and potential. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Forward looking statements and information do not constitute guarantees of future performances, and are subject to known or unknown risks, uncertainties and other factors, a large number of which are difficult to predict and generally outside the control of the Group, which could cause actual results, performances or achievements, or the results of the sector or other events, to differ materially from those described or suggested by these forward-looking statements. These risks and uncertainties include those that are indicated and detailed in Chapter 3 'Risk factors' of the Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers, AMF) on April 1, 2025. These forward-looking statements are given only as of the date of this press release and the Group expressly declines any obligation or commitment to publish updates or corrections of the forward-looking statements included in this press release in order to reflect any change affecting the forecasts or events, conditions or circumstances on which these forward-looking statements are based. Attachment EUROAPI - Press release - June 4, 2025Sign in to access your portfolio

Trump says he would back GOP Rep. Meuser for Pennsylvania governor bid
Trump says he would back GOP Rep. Meuser for Pennsylvania governor bid

Yahoo

time31-05-2025

  • Yahoo

Trump says he would back GOP Rep. Meuser for Pennsylvania governor bid

President Trump on Friday offered his support for Rep. Dan Meuser (R-Pa.) if the congressman opts to run for governor in Pennsylvania, which Meuser has said he is considering. Trump quipped during a rally in Pittsburgh that he heard a 'rumor' that Meuser was weighing a gubernatorial bid, which would pit him against Gov. Josh Shapiro (D). 'If that's your decision you've got my support,' Trump said. 'He's been a great congressman,' Trump added. 'And if you run, you have my support. And you'll win. The people are going to get it real fast.' Mueser told The Hill in January he was seriously considering challening Shapiro in the 2026 election. 'I'm considering it,' Meuser told The Hill. 'I mean if I get in it's because I think I can win and that means beating the incumbent, which is Josh Shapiro. So it's no easy task.' Meuser has represented Pennsylvania's 9th Congressional District since 2019. He previously served as the state's secretary of revenue from 2011-15. Shapiro defeated his Republican opponent, state Sen. Doug Mastriano, in 2022 with 56 percent of the vote. While Mastrano was considered a weak general election candidate, Shapiro has continued to maintain his popularity within the state while building a national profile. He is considered a potential presidential candidate for 2028. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store